Post-marketing Clinical Study of IZCARGO in Patients with Mucopolysaccharidosis Type II
Post-marketing Clinical Study of IZCARGO in Patients with Mucopolysaccharidosis Type II
mucopolysaccharidosis type II (MPS II)
[Post-marketing clinical study drug] Name - Post-marketing clinical study drug (code): IZCARGO for I.V. infusion 10 mg (test drug code: JR-141) - Nonproprietary name International nonproprietary name (INN): pabinafusp alfa (r-INN List 82, WHO Drug Information, Vol. 33. No. 3, 2019) Japanese accepted names for pharmaceuticals (JAN) Registered number: 301-4-B3 Japanese name: pabinafusp alfa (genetical recombination) English name: Pabinafusp Alfa (Genetical Recombination) Dose and regimen: Subjects will receive 2.0 mg of pabinafusp alfa (genetical recombination) per kilogram of body weight once a week as an intravenous infusion. [Post-marketing clinical study drug] Name - Post-marketing clinical study drug (code): IZCARGO for I.V ...